These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on Cancer. Lotem M; Peretz T; Drize O; Gimmon Z; Ad El D; Weitzen R; Goldberg H; Ben David I; Prus D; Hamburger T; Shiloni E Br J Cancer; 2002 May; 86(10):1534-9. PubMed ID: 12085200 [TBL] [Abstract][Full Text] [Related]
4. Generation in vitro of B-cell chronic lymphocytic leukaemia-proliferative and specific HLA class-II-restricted cytotoxic T-cell responses using autologous dendritic cells pulsed with tumour cell lysate. Goddard RV; Prentice AG; Copplestone JA; Kaminski ER Clin Exp Immunol; 2001 Oct; 126(1):16-28. PubMed ID: 11678895 [TBL] [Abstract][Full Text] [Related]
5. Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response. Russo V; Tanzarella S; Dalerba P; Rigatti D; Rovere P; Villa A; Bordignon C; Traversari C Proc Natl Acad Sci U S A; 2000 Feb; 97(5):2185-90. PubMed ID: 10681453 [TBL] [Abstract][Full Text] [Related]
6. Enhancing antitumor immune responses: intracellular peptide delivery and identification of MHC class II-restricted tumor antigens. Wang RF Immunol Rev; 2002 Oct; 188():65-80. PubMed ID: 12445282 [TBL] [Abstract][Full Text] [Related]
7. MHC-restricted recognition of autologous melanoma by tumor-specific cytotoxic T cells. Evidence for restriction by a dominant HLA-A allele. Crowley NJ; Darrow TL; Quinn-Allen MA; Seigler HF J Immunol; 1991 Mar; 146(5):1692-9. PubMed ID: 1671580 [TBL] [Abstract][Full Text] [Related]
8. Small cell lung carcinomas express shared and private tumor antigens presented by HLA-A1 or HLA-A2. Yamazaki K; Spruill G; Rhoderick J; Spielman J; Savaraj N; Podack ER Cancer Res; 1999 Sep; 59(18):4642-50. PubMed ID: 10493519 [TBL] [Abstract][Full Text] [Related]
9. Synthetic peptides derived from the melanocyte-stimulating hormone receptor MC1R can stimulate HLA-A2-restricted cytotoxic T lymphocytes that recognize naturally processed peptides on human melanoma cells. Salazar-Onfray F; Nakazawa T; Chhajlani V; Petersson M; Kärre K; Masucci G; Celis E; Sette A; Southwood S; Appella E; Kiessling R Cancer Res; 1997 Oct; 57(19):4348-55. PubMed ID: 9331097 [TBL] [Abstract][Full Text] [Related]
10. Generation of human autologous melanoma-specific cytotoxic T-cells using HLA-A2-matched allogeneic melanomas. Crowley NJ; Slingluff CL; Darrow TL; Seigler HF Cancer Res; 1990 Feb; 50(3):492-8. PubMed ID: 2404572 [TBL] [Abstract][Full Text] [Related]
11. Generation of primary tumor-specific cytotoxic T lymphocytes from autologous and human lymphocyte antigen class I-matched allogeneic peripheral blood lymphocytes by B7 gene-modified melanoma cells. Yang S; Darrow TL; Seigler HF Cancer Res; 1997 Apr; 57(8):1561-8. PubMed ID: 9108460 [TBL] [Abstract][Full Text] [Related]
12. Major histocompatibility complex class I restricted cytotoxic T cells specific for natural melanoma peptides recognize unidentified shared melanoma antigen(s). Imro MA; Manici S; Russo V; Consogno G; Bellone M; Rugarli C; Traversari C; Protti MP Cancer Res; 1999 May; 59(10):2287-91. PubMed ID: 10344730 [TBL] [Abstract][Full Text] [Related]
13. Identification of genes coding for tumor antigens recognized by cytolytic T lymphocytes. De Plaen E; Lurquin C; Lethé B; van der Bruggen P; Brichard V; Renauld JC; Coulie P; Van Pel A; Boon T Methods; 1997 Jun; 12(2):125-42. PubMed ID: 9184377 [TBL] [Abstract][Full Text] [Related]